Ruxolitinib in Patients With Breast Cancer

Summary

Ruxolitinib is a drug which blocks the Janus tyrosine Kinase (JAK) signaling pathway. It is thought that this pathway might be important in certain types of breast cancer, and that blocking this pathway might lead to anti-cancer effects. This study is testing the effects of ruxolitinib in patients with breast cancer.

Timeline

Start

2012-06

Primary completion

2015-06

Completion

2016-06

Outcome

Outcome not reported

Stopped: “Not enough responses to continue treatment.”

Drugs

Indications